Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 94,917	$ 130,101
Marketable securities, short-term	120,517	47,504
Prepaid expenses and other current assets	3,164	2,724
Total current assets	218,598	180,329
Marketable securities, long-term	67,270	15,837
Restricted cash	189	0
Property and equipment, net	123	165
Right-of-use asset	2	105
Other assets	189	151
Total assets	286,371	196,587
Current liabilities
Accounts payable	1,362	1,640
Accrued clinical trial expenses	1,566	2,717
Accrued expenses and other current liabilities	3,168	3,350
Operating lease liability	2	105
Total current liabilities	6,098	7,812
Total liabilities	6,098	7,812
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 57,910,461 and 41,025,062 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	6	4
Additional paid-in capital	487,077	359,949
Accumulated deficit	(206,301)	(170,427)
Accumulated other comprehensive loss	(509)	(751)
Total stockholders’ equity	280,273	188,775
Total liabilities and stockholders’ equity	$ 286,371	$ 196,587